Sun-373 Comparison of Low-Dose Intravenous Cyclophosphamide With Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis- Extended Follow-Up Data

Abstract

The largest sample size to date is the strength of the study and we conclude CD-19 targeted rituximab is a safe and effective agent in the management of adults with SD/CNI dependent MCD/FSGS. At 12 months, over three-fourth of the patients with SD/CNI dependent podocytopathy maintain clinical remission.